Borderline Personality Disorder
Conditions
Interventions
This is an open-label, two-arm, randomized controlled clinical trial. Adolescents who meet the participation criteria will be allocated to one or the other intervention group using a randomization pla
F02.784.629.937
Sponsors
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Eligibility
Age
13 Years to 17 Years
Inclusion criteria
Inclusion criteria: Adolescents; literate; aged 13-17 years; all genders; both sex; with 3 or more criteria for Borderline Personality Disorder; agree to sign the Informed Consent Form
Exclusion criteria
Exclusion criteria: Adolescents with intellectual disabilities (IQ<80); primary psychoses; decompensated bipolar affective disorder; decompensated anorexia; severe neurological problems; conduct disorder with limited pro-social emotions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome will be the difference in the BSL-23 score at six months, when compared to BSL-23 score at baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome will be the difference in the BAI score at six months, when compared to BAI score at baseline.;Secondary outcome will be the difference in the BDI-II score at six months, when compared to BDI-II score at baseline.;Secondary outcome will be the difference in the BHS score at six months, when compared to BHS score at baseline.;Secondary outcome will be the difference in the EOMEIS-2 domains scores at six months, when compared to EOMEIS-2 domains scores at baseline.;Secondary outcome will be the difference in the RSS score at six months, when compared to RSS score at baseline.;Secondary outcome will be the difference in the SCL-90-R Global Severity Index (GSI) and Subscales scores at six months, when compared to SCL-90-R Global Severity Index (GSI) and Subscales scores at baseline.;Secondary outcome will be the difference in the MHC-SF total score at six months, when compared to MHC-SF total score at baseline.;Secondary outcome will be the difference in the MSLSS total score and subscales score at six months, when compared to MSLSS total score and subscales score at baseline.;Secondary outcome will be the difference in the SAS-SR total score at six months, when compared to SAS-SR total score at baseline.;Secondary outcome will be the difference in the YQOL-R total score at six months, when compared YQOL-R total score at baseline.;To compare variations in clinical symptoms (BAI, BDI-II, BSL-23, BHS, EOMEIS-2, RSS, and SCL-90-R) before intervention, 6 months after the beginning of intervention, and 12 months after the beginning of intervention in each group, using ANOVA with repeated-measures. ;To compare variations in clinical symptoms (BAI, BDI-II, BSL-23, BHS, EOMEIS-2, RSS, and SCL-90-R) at 6 months and 12 months after the beginning of intervention in each group, using ANOVA with repeated-measures. ;To compare variations in positive mental health (MHC-SF, MSLSS, SAS-SR, and YQOL-R) before intervention, 6 months after the beginning of intervention, a | — |
Countries
Brazil
Contacts
Public ContactJúlia Gerotto
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Outcome results
None listed